Subsequently, a multicentre phase-2 trial (NCT03276468) assessed the antilymphoma activity of atorolimumab associated with Veneto lax (a BCL-2 inhibitor) and blinatumomab in three cohorts: R/R FL patients, R/R DLBCL patients and iNHLs, including MZL and MALT cases. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.